{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:52:16Z","timestamp":1788245536438,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:00:00Z","timestamp":1767484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006196","name":"Jet Propulsion Laboratory","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH R37 \\u2013 1R37CA292075-01"],"award-info":[{"award-number":["NIH R37 \\u2013 1R37CA292075-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.esmoop.2026.106059","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T17:03:29Z","timestamp":1772643809000},"page":"106059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Genomic landscape, immune microenvironment and survival in male versus female breast cancer"],"prefix":"10.1016","volume":"11","author":[{"given":"D.","family":"Trapani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.K.","family":"Deshmukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3468-7165","authenticated-orcid":false,"given":"T.","family":"Samec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Xiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.L.","family":"Abravanel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8644-0178","authenticated-orcid":false,"given":"P.M.","family":"Spanheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.U.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"G.","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1928-1722","authenticated-orcid":false,"given":"S.L.","family":"Graff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lustberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.W.","family":"Sledge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5940-8671","authenticated-orcid":false,"given":"S.M.","family":"Tolaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8537-652X","authenticated-orcid":false,"given":"J.P.","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2026.106059_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106059_bib2","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmoop.2026.106059_bib3","first-page":"1","article-title":"Male breast cancer: an updated review of epidemiology, clinicopathology, and treatment","volume":"2022","author":"Zheng","year":"2022","journal-title":"J Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106059_bib4","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1001\/jamaoncol.2022.7173","article-title":"Cancer in transgender and gender-diverse persons: a review","volume":"9","author":"Leone","year":"2023","journal-title":"JAMA Oncol"},{"issue":"16","key":"10.1016\/j.esmoop.2026.106059_bib5","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1158\/1078-0432.CCR-15-2840","article-title":"The genomic landscape of male breast cancers","volume":"22","author":"Piscuoglio","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106059_bib6","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s10549-021-06182-y","article-title":"Tumor subtypes and survival in male breast cancer","volume":"188","author":"Leone","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"24","key":"10.1016\/j.esmoop.2026.106059_bib7","doi-asserted-by":"crossref","first-page":"5721","DOI":"10.3390\/cancers15245721","article-title":"The genomic landscape of urothelial carcinoma with high and low ERBB2 expression","volume":"15","author":"Hadadi","year":"2023","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106059_bib8","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nmeth.4197","article-title":"Salmon provides fast and bias-aware quantification of transcript expression","volume":"14","author":"Patro","year":"2017","journal-title":"Nat Methods"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106059_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-019-0638-6","article-title":"Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data","volume":"11","author":"Finotello","year":"2019","journal-title":"Genome Med"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106059_bib10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13073-020-00787-6","article-title":"Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types","volume":"12","author":"Bao","year":"2020","journal-title":"Genome Med"},{"issue":"6411","key":"10.1016\/j.esmoop.2026.106059_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade\u2013based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106059_bib12","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2026.106059_bib13","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ygyno.2023.08.015","article-title":"Differential outcomes and immune checkpoint inhibitor response among endometrial cancer patients with MLH1 hypermethylation versus MLH1 \u201cLynch-like\u201d mismatch repair gene mutation","volume":"177","author":"Toboni","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106059_bib14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s12032-023-02071-0","article-title":"Capicua (CIC) mutations in gliomas in association with MAPK activation for exposing a potential therapeutic target","volume":"40","author":"Darabi","year":"2023","journal-title":"Med Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106059_bib15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/jnci\/djab169","article-title":"Homologous recombination deficiency alterations in colorectal cancer: clinical, molecular, and prognostic implications","volume":"114","author":"Moretto","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106059_bib16","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.5858\/134.7.e48","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version)","volume":"134","author":"Hammond","year":"2010","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106059_bib17","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/annonc\/mdx651","article-title":"Characterization of male breast cancer: results of the EORTC 10085\/TBCRC\/BIG\/NABCG International Male Breast Cancer Program","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.esmoop.2026.106059_bib18","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1200\/JCO.19.03120","article-title":"Management of male breast cancer: ASCO guideline","volume":"38","author":"Hassett","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106059_bib19","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s10549-017-4533-9","article-title":"Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer","volume":"167","author":"Rimawi","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"21","key":"10.1016\/j.esmoop.2026.106059_bib20","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1002\/cncr.34448","article-title":"Efficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast cancer","volume":"128","author":"Leone","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2026.106059_bib21","article-title":"PIK3CA mutations drive therapeutic resistance in human epidermal growth factor receptor 2\u2013positive breast cancer","volume":"6","author":"Rasti","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"33","key":"10.1016\/j.esmoop.2026.106059_bib22","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.2013.54.5384","article-title":"Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2\u2013positive, first-line metastatic breast cancer","volume":"32","author":"Baselga","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106059_bib23","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13058-024-01872-z","article-title":"Genomic profiling and comparative analysis of male versus female metastatic breast cancer across subtypes","volume":"26","author":"Kadamkulam Syriac","year":"2024","journal-title":"Breast Cancer Res"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106059_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100100","article-title":"p53 Expression in luminal breast cancer correlates with TP53 mutation and primary endocrine resistance","volume":"36","author":"Mueller","year":"2023","journal-title":"Mod Pathol"},{"issue":"21","key":"10.1016\/j.esmoop.2026.106059_bib25","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.18632\/oncotarget.28071","article-title":"TP53 mutations determined by targeted NGS in breast cancer: a case-control study","volume":"12","author":"Andrikopoulou","year":"2021","journal-title":"Oncotarget"},{"issue":"16","key":"10.1016\/j.esmoop.2026.106059_bib26","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1158\/1078-0432.CCR-22-0305","article-title":"Overall survival with palbociclib and fulvestrant in women with HR+\/HER2\u2212 ABC: updated exploratory analyses of PALOMA-3, a double-blind, phase III randomized study","volume":"28","author":"Cristofanilli","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106059_bib27","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41523-022-00426-w","article-title":"Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer","volume":"8","author":"Li","year":"2022","journal-title":"npj Breast Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106059_bib28","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41568-023-00604-3","article-title":"Therapeutic resistance to anti-oestrogen therapy in breast cancer","volume":"23","author":"Will","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.esmoop.2026.106059_bib29","article-title":"Systematic review of molecular biomarkers predictive of resistance to CDK4\/6 inhibition in metastatic breast cancer","volume":"6","author":"Asghar","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.106059_bib30","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2024.10852","article-title":"Germline CDH1 variants and lifetime cancer risk","volume":"332","author":"Ryan","year":"2024","journal-title":"J Am Med Assoc"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106059_bib31","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1136\/jmedgenet-2015-103094","article-title":"Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers","volume":"52","author":"van der Post","year":"2015","journal-title":"J Med Genet"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106059_bib32","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1002\/cncr.23501","article-title":"Hereditary diffuse gastric cancer: diagnosis, genetic counseling, and prophylactic total gastrectomy","volume":"112","author":"Lynch","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106059_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12998\/wjcc.v6.i1.1","article-title":"Hereditary diffuse gastric cancer: one family\u2019s story","volume":"6","author":"Zylberberg","year":"2018","journal-title":"World J Clin Cases"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106059_bib34","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10549-016-3768-1","article-title":"Prognostic factors in male breast cancer: a population-based study","volume":"156","author":"Leone","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106059_bib35","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/oncolo\/oyad049","article-title":"Revisiting androgen receptor signaling in breast cancer","volume":"28","author":"Dai","year":"2023","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106059_bib36","doi-asserted-by":"crossref","first-page":"R27","DOI":"10.1530\/ERC-16-0225","article-title":"A review of estrogen receptor\/androgen receptor genomics in male breast cancer","volume":"24","author":"Severson","year":"2017","journal-title":"Endocr-Relat Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106059_bib37","first-page":"6852","article-title":"Male breast carcinoma: a clinicopathological and immunohistochemical characterization study","volume":"7","author":"Zhou","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106059_bib38","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s11523-018-0610-1","article-title":"PD-1 and PD-L1 expression in male breast cancer in comparison with female breast cancer","volume":"13","author":"Manson","year":"2018","journal-title":"Target Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106059_bib39","doi-asserted-by":"crossref","first-page":"818","DOI":"10.3390\/ijms24010818","article-title":"Tumor microenvironment in male breast carcinoma with emphasis on tumor infiltrating lymphocytes and PD-L1 expression","volume":"24","author":"Brcic","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106059_bib40","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.clbc.2021.04.014","article-title":"Management of breast cancer patients during the coronavirus disease 2019 pandemic: the experience from the epicenter of China, Wuhan","volume":"22","author":"Zhou","year":"2022","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106059_bib41","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/COC.0000000000000497","article-title":"Overall survival of men and women with breast cancer according to tumor subtype: a population-based study","volume":"42","author":"Leone","year":"2019","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106059_bib42","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10549-015-3488-y","article-title":"Prognostic significance of tumor subtypes in male breast cancer: a population-based study","volume":"152","author":"Leone","year":"2015","journal-title":"Breast Cancer Res Treat"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926000013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926000013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T01:14:39Z","timestamp":1774487679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926000013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2059702926000013"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106059","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomic landscape, immune microenvironment and survival in male versus female breast cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106059"}}